| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 2564380 | Pharmacology & Therapeutics | 2006 | 12 Pages | 
Abstract
												Mitoxantrone is approved by several health authorities for treatment of active forms of relapsing-remitting or secondary progressive multiple sclerosis (SPMS). This review provides an outline on relevant preclinical as well as clinical studies, places mitoxantrone in the context of other therapeutic approaches against multiple sclerosis (MS), and discusses relevant side effects. The current knowledge of the putative mechanisms of action of the compound is discussed.
Keywords
												
											Related Topics
												
													Health Sciences
													Pharmacology, Toxicology and Pharmaceutical Science
													Pharmacology
												
											Authors
												Oliver Neuhaus, Bernd C. Kieseier, Hans-Peter Hartung, 
											